Baxter Stock Plunges 7%, Wiping Out $962 Million, Despite Raised 2026 Outlook

Adjusted profit per share fell on a higher tax rate, and Baxter said it will stop making cephalosporin drugs at its Round Lake plant.

Share
Baxter Stock Plunges 7%, Wiping Out $962 Million, Despite Raised 2026 Outlook

Baxter International shares fell 7.31% to $23.60 in Thursday trading, as of 1:30 p.m. ET, erasing $962 million in market value, the day after the company lifted its 2026 outlook while reporting that third-quarter adjusted earnings per share fell from a year earlier on a higher tax rate.

Revenue up, adjusted profit down

Baxter reported third-quarter adjusted earnings of 58 cents a share, down from 69 cents a year earlier. Revenue rose to $2.98 billion from $2.84 billion.

The company now expects full-year adjusted earnings of $2.05 to $2.15 a share, up from a prior range of $1.95 to $2.15. Third-quarter free cash flow was $448 million, the company said, as it completed a tender offer to reduce debt.

On the earnings call, management said Baxter will stop making cephalosporin drugs at its Round Lake plant, giving up $30 million of 2026 operating income. The call linked the exit to an FDA warning letter.

Giving back a 33% run

Baxter makes healthcare products, including IV solutions, infusion systems, generic injectable drugs and respiratory devices, for hospitals, nursing homes, dialysis centers and patients at home. It reports three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals.

The stock was up about 33% year to date as of Wednesday's close, against about 13% for the S&P 500. Thursday's drop put it on pace for its biggest one-day fall since February 12, when it dropped 16.0%.

CEO Andrew Hider said on the call that a competitor's supply trouble was "not a small piece" of double-digit growth in the Advanced Surgery unit, and warned of tougher comparisons ahead.

Hider's warning of tougher comparisons in Advanced Surgery came on the same call that raised the full-year range.

Sources

More on Baxter International

All Baxter International (BAX) coverage →